歐菲光(002456.SZ):擬推不超2.66億股的2021年股票期權激勵計劃
格隆匯9月27日丨歐菲光(002456.SZ)公佈2021年股票期權激勵計劃(草案),該激勵計劃擬授權的股票期權數量為不超過2.66億股,約佔該激勵計劃草案公吿時公司股本總額32.62億股的8.15%。
其中首次授權2.54億股,約佔該計劃草案公吿時公司股本總額的7.78%;預留1229.40萬股,約佔該計劃草案公吿時公司股本總額的0.38%,預留部分佔股票期權擬授權總額的4.62%。
該激勵計劃首次授權的股票期權行權價格為8.33元/股。
該激勵計劃首次授權的激勵對象不超過2761人。該激勵計劃有效期自股票期權首次授權日起至全部行權或註銷之日止,最長不超過72個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.